Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial

BACKGROUND: The response to neoadjuvant chemotherapy (NAC) varies by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses, with responses being lower in ER-positive, HER2-negative tumors as compared with ER-negative, HER2-positive or triple-negative tumors. Neoadjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wei, Deng, Heran, Rao, Nanyan, You, Na, Yang, Yaping, Cao, Minghui, Liu, Jieqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655944/
https://www.ncbi.nlm.nih.gov/pubmed/29070044
http://dx.doi.org/10.1186/s13063-017-2228-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655944/
https://www.ncbi.nlm.nih.gov/pubmed/29070044
http://dx.doi.org/10.1186/s13063-017-2228-5

Ejemplares similares